risperidone has been researched along with Neuroleptic Malignant Syndrome in 98 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To report the case of a 53-year-old patient who developed neuroleptic malignant syndrome (NMS) - a rare but potentially life-threatening complication of neuroleptic therapy - 4 days after treatment with risperidone was initiated." | 8.79 | Risperidone-induced neuroleptic malignant syndrome: a case report and review. ( Meterissian, GB, 1996) |
| "Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS)." | 7.83 | Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? ( Cherry, S; Halangoda, P; Siskind, D; Spivak, V; Wysoczanski, D, 2016) |
| " Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia." | 7.75 | A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. ( De Sarro, G; Ferraro, M; Gallelli, L; Palleria, C; Spagnuolo, V, 2009) |
| "To report and discuss a case of neuroleptic malignant syndrome (NMS) with delayed onset of fever in a patient taking risperidone." | 7.73 | Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. ( Angeles, V; Eisenstein, R; Norris, B; Seale, JP, 2006) |
| "A 39-year-old man with schizophrenia developed severe catatonia, hyperthermia, muscle rigidity, tachycardia, leukocytosis, and elevated muscle enzyme levels while receiving zotepine therapy." | 7.73 | Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. ( Chen, CC; Tsai, JH; Yang, MJ; Yang, P; Yen, JY, 2005) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 7.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 7.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| "A 57-year-old African-American man, treated for schizophrenia with haloperidol for several years, developed NMS within 48 hours of the addition of low doses of risperidone and mirtazapine to his regimen." | 7.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "We present a case of a 74-year-old patient with schizoaffective disorder, who developed risperidone-related neuroleptic malignant syndrome." | 7.70 | High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. ( Devarajan, S; Dursun, SM; Kutcher, SP; Oluboka, OJ, 1998) |
| "To describe a case of neuroleptic malignant syndrome associated with risperidone." | 7.69 | Neuroleptic malignant syndrome and risperidone: a case report. ( Bonwick, RJ; Hopwood, MJ; Morris, PL, 1996) |
| "Neuroleptic malignant syndrome is a rare neuropsychiatric complication caused by antipsychotic drugs." | 5.72 | [Neuroleptic malignant syndrome caused by olanzapine, risperidone and haloperidol]. ( Boesen, MS; Ladefoged, MR; Marloth, PV, 2022) |
| "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis." | 5.35 | Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. ( Akin, R; Altun, D; Congologlu, A; Unay, B; Vurucu, S, 2009) |
| "Risperidone is an antipsychotic drug used for the treatment of schizophrenia." | 5.30 | Risperidone-induced neuroleptic malignant syndrome. ( Bajjoka, I; O'Sullivan, T; Patel, T, 1997) |
| "We found only one small, short-term trial suggesting that risperidone may improve catatonic and positive symptoms scale scores amongst people with schizophrenia spectrum disorders and catatonic symptoms, but that ECT may result in greater improvement in the first three weeks of treatment." | 5.22 | Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. ( Caroff, SN; Gibson, RC; Huang, MW; Jayaram, MB, 2022) |
| "To retrospectively examine published cases of neuroleptic malignant syndrome (NMS) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole)." | 4.84 | Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. ( Croarkin, PE; Emslie, GJ; Mayes, TL, 2008) |
| "Nine of the 19 cases of clozapine-related neuroleptic malignant syndrome and eight of the 13 cases of risperidone-related neuroleptic malignant syndrome were designated as having high probability of being neuroleptic malignant syndrome." | 4.80 | Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. ( Buckley, P; Hasan, S, 1998) |
| " To report the case of a 53-year-old patient who developed neuroleptic malignant syndrome (NMS) - a rare but potentially life-threatening complication of neuroleptic therapy - 4 days after treatment with risperidone was initiated." | 4.79 | Risperidone-induced neuroleptic malignant syndrome: a case report and review. ( Meterissian, GB, 1996) |
| "We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels." | 3.96 | Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation. ( Ayanoğlu, M; Aydin, HI; Korgali, E; Sezer, T; Sönmez, FM, 2020) |
| "Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS)." | 3.83 | Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? ( Cherry, S; Halangoda, P; Siskind, D; Spivak, V; Wysoczanski, D, 2016) |
| " The Naranjo probability scale indicated probable causality for NMS due to quetiapine, haloperidol, and risperidone in this patient, whereas the Naranjo scale assigned only possible causality for serotonin syndrome developing with serotonergic agents." | 3.77 | Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. ( Ariano, RE; Sokoro, AA; Zivot, J, 2011) |
| " Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia." | 3.75 | A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. ( De Sarro, G; Ferraro, M; Gallelli, L; Palleria, C; Spagnuolo, V, 2009) |
| "To report and discuss a case of neuroleptic malignant syndrome (NMS) with delayed onset of fever in a patient taking risperidone." | 3.73 | Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. ( Angeles, V; Eisenstein, R; Norris, B; Seale, JP, 2006) |
| "A 39-year-old man with schizophrenia developed severe catatonia, hyperthermia, muscle rigidity, tachycardia, leukocytosis, and elevated muscle enzyme levels while receiving zotepine therapy." | 3.73 | Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. ( Chen, CC; Tsai, JH; Yang, MJ; Yang, P; Yen, JY, 2005) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 3.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 3.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine." | 3.71 | Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure. ( Fukasawa, T; Hayashi, H; Kawakatsu, S; Otani, K; Watanabe, K, 2002) |
| "A 57-year-old African-American man, treated for schizophrenia with haloperidol for several years, developed NMS within 48 hours of the addition of low doses of risperidone and mirtazapine to his regimen." | 3.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "We present a case of a 74-year-old patient with schizoaffective disorder, who developed risperidone-related neuroleptic malignant syndrome." | 3.70 | High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. ( Devarajan, S; Dursun, SM; Kutcher, SP; Oluboka, OJ, 1998) |
| "To describe a case of neuroleptic malignant syndrome associated with risperidone." | 3.69 | Neuroleptic malignant syndrome and risperidone: a case report. ( Bonwick, RJ; Hopwood, MJ; Morris, PL, 1996) |
| "Haloperidol was also associated with a significant increase of peripheral blood mononuclear cell membrane peroxidation." | 2.73 | Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. ( Bernardo, M; Cardellach, F; Casademont, J; Garrabou, G; López, S; Miró, O; Pons, A, 2007) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| "Serotonin syndrome and neuroleptic malignant syndrome are two drug toxidromes that have often overlapping and confusing clinical pictures." | 2.50 | Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. ( Ambaliya, A; Dosi, R; Joshi, H; Patell, R, 2014) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| "However, other side effects of seizures, sedation, neuroleptic malignant syndrome and cardiovascular, hematologic, endocrinological, and weight gain problems remain as clinical management challenges posed by existing antipsychotic drug therapy." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "A 55-year-old woman with a history of mental retardation and infantile psychosis is hospitalized for worsening of her psychiatric symptoms." | 1.43 | [Case report: Neuroleptic malignant syndrome and diagnostic difficulties]. ( Khouri, C; Logerot, S; Mallaret, M; Planès, S; Villier, C, 2016) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| "Risperidone was discontinued and, owing to ongoing psychosis, olanzapine was initiated." | 1.38 | Antipsychotics leading to neuroleptic malignant syndrome in pregnancy. ( Aghajanian, P; Dossett, E; Ghaffari, N; Lee, RH, 2012) |
| "The treatment with haloperidol more often results in movement disorders, sleepiness, inhibition, sexual dysfunction and cholinolytic effects." | 1.35 | [Peculiarities of neuroleptic syndrome in women treated with typical and atypical neuroleptics]. ( Chitaia, NN; Danilov, DS; Tiuvina, NA, 2009) |
| "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis." | 1.35 | Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. ( Akin, R; Altun, D; Congologlu, A; Unay, B; Vurucu, S, 2009) |
| "Tardive seizure is a serious adverse reaction of electroconvulsive therapy (ECT)." | 1.35 | Tardive seizure and antibiotics: case reports and review of the literature. ( Isse, K; Nakamura, M; Saito, T; Watari, M, 2008) |
| "Rhabdomyolysis is a disorder characterized by skeletal muscle injury and fatal complications at times." | 1.32 | [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]. ( Busiello, L; Cascella, M; De Robertis, E; Di Domenico, MG; Palmese, S; Pezza, M, 2003) |
| "The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0." | 1.32 | Neuroleptic malignant syndrome and atypical antipsychotic drugs. ( Ananth, J; Burgoyne, K; Gunatilake, S; Parameswaran, S; Sidhom, T, 2004) |
| "The diagnosis of neuroleptic malignant syndrome was made on the basis of the clinical picture accomplished whole of biochemical, figurative tests as well as on the conducted differential diagnostics." | 1.31 | [Neuroleptic malignant syndrome--case report]. ( Kroczak, M; Rakus, A, 2001) |
| "Differential diagnosis between neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) could not be accurately determined because of the overlap of signs and symptoms of both syndromes." | 1.31 | Neurotoxic syndrome associated with risperidone and fluvoxamine. ( Beddingfield, JJ; Mack, JE; Reeves, RR, 2002) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (26.53) | 18.2507 |
| 2000's | 48 (48.98) | 29.6817 |
| 2010's | 18 (18.37) | 24.3611 |
| 2020's | 6 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, MW | 1 |
| Gibson, RC | 1 |
| Jayaram, MB | 1 |
| Caroff, SN | 2 |
| Marloth, PV | 1 |
| Ladefoged, MR | 1 |
| Boesen, MS | 1 |
| Matos, CRC | 1 |
| Beirão, EMDCSP | 1 |
| Neves, RS | 1 |
| Assunção, AJ | 1 |
| Marques, RM | 1 |
| Ayanoğlu, M | 1 |
| Korgali, E | 1 |
| Sezer, T | 1 |
| Aydin, HI | 1 |
| Sönmez, FM | 1 |
| Prakash, S | 1 |
| Lodha, D | 1 |
| Rawat, KS | 1 |
| Mitchell, BG | 1 |
| McMahon, BC | 1 |
| Mitchell, CW | 1 |
| Morcos, M | 1 |
| Corns, J | 1 |
| Hillen, JB | 1 |
| Vellekkatt, F | 1 |
| Kuppili, PP | 1 |
| Bharadwaj, B | 1 |
| Menon, V | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Dosi, R | 1 |
| Ambaliya, A | 1 |
| Joshi, H | 1 |
| Patell, R | 1 |
| Takeuchi, D | 1 |
| Ono, T | 1 |
| Wada, Y | 1 |
| Guru, S | 1 |
| Vanamoorthy, U | 1 |
| Loganathan, S | 1 |
| Varghese, M | 1 |
| Kazdal, H | 1 |
| Kanat, A | 1 |
| Sen, A | 1 |
| Kirbas, S | 1 |
| Ardic, G | 1 |
| Tufekci, A | 1 |
| Ersoz, T | 1 |
| Khouri, C | 1 |
| Planès, S | 1 |
| Logerot, S | 1 |
| Villier, C | 1 |
| Mallaret, M | 1 |
| Cherry, S | 1 |
| Siskind, D | 1 |
| Spivak, V | 1 |
| Wysoczanski, D | 1 |
| Halangoda, P | 1 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Pasa, S | 1 |
| Sayhan, MB | 1 |
| Boyraz, T | 1 |
| Urakci, Z | 1 |
| Altintas, A | 1 |
| Carey, S | 1 |
| Croarkin, PE | 1 |
| Emslie, GJ | 1 |
| Mayes, TL | 1 |
| Saito, T | 1 |
| Nakamura, M | 1 |
| Watari, M | 1 |
| Isse, K | 1 |
| Mall, GD | 1 |
| Hake, L | 1 |
| Benjamin, AB | 1 |
| Adityanjee, A | 1 |
| Ladds, B | 1 |
| Thomas, P | 1 |
| Mejia, C | 1 |
| Hauser, D | 1 |
| Vurucu, S | 1 |
| Congologlu, A | 1 |
| Altun, D | 1 |
| Unay, B | 1 |
| Akin, R | 1 |
| Chitaia, NN | 1 |
| Danilov, DS | 1 |
| Tiuvina, NA | 1 |
| Gallelli, L | 1 |
| Spagnuolo, V | 1 |
| Palleria, C | 1 |
| De Sarro, G | 1 |
| Ferraro, M | 1 |
| Ghio, L | 1 |
| Fornaro, G | 1 |
| Rossi, P | 1 |
| Davies, MA | 1 |
| Conley, Y | 1 |
| Roth, BL | 1 |
| Zivković, M | 1 |
| Mihaljević-Peles, A | 1 |
| Sagud, M | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Sokoro, AA | 1 |
| Zivot, J | 1 |
| Ariano, RE | 1 |
| Teng, PR | 1 |
| Lane, HY | 1 |
| Ghaffari, N | 1 |
| Dossett, E | 1 |
| Lee, RH | 1 |
| Aghajanian, P | 1 |
| Motomura, E | 1 |
| Tanii, H | 1 |
| Usami, A | 1 |
| Ohoyama, K | 1 |
| Nakagawa, M | 1 |
| Okada, M | 1 |
| Yamashita, T | 1 |
| Fujii, Y | 1 |
| Misawa, F | 1 |
| Hayashi, H | 1 |
| Kawakatsu, S | 1 |
| Watanabe, K | 1 |
| Fukasawa, T | 1 |
| Otani, K | 1 |
| Beauchemin, MA | 1 |
| Millaud, F | 1 |
| Nguyen, KA | 1 |
| Bourgeois, JA | 1 |
| Kahn, DR | 1 |
| Pezza, M | 1 |
| Busiello, L | 1 |
| Palmese, S | 1 |
| Cascella, M | 1 |
| Di Domenico, MG | 1 |
| De Robertis, E | 1 |
| Vercammen, L | 1 |
| Buyse, GM | 1 |
| Proost, JE | 1 |
| Van Hove, JL | 1 |
| Ananth, J | 2 |
| Parameswaran, S | 1 |
| Gunatilake, S | 1 |
| Burgoyne, K | 1 |
| Sidhom, T | 1 |
| Johnson, KM | 1 |
| Levander, EM | 1 |
| Harry, JL | 1 |
| Gerritsen, AA | 1 |
| de Jonghe-Rouleau, AP | 1 |
| Stienstra-Liem, LH | 1 |
| van Waarde, JA | 1 |
| Kuiper, J | 1 |
| Verwey, B | 1 |
| Kroon, JG | 1 |
| Bonte-Mineur, F | 1 |
| Geerlings, CJ | 1 |
| Rietveld, AP | 1 |
| Vorel, SK | 1 |
| Bos, F | 1 |
| Vorel-Havelkova, E | 1 |
| Brombacher, PJ | 1 |
| Ellard, J | 1 |
| van Bemmel, T | 1 |
| Westendorp, RG | 1 |
| Chungh, DS | 1 |
| Kim, BN | 1 |
| Cho, SC | 1 |
| Del Tacca, M | 1 |
| Lattanzi, L | 1 |
| Lastella, M | 1 |
| Di Paolo, A | 1 |
| Mungai, F | 1 |
| Danesi, R | 1 |
| Menichetti, F | 1 |
| Dell'osso, L | 1 |
| Cassano, GB | 1 |
| Tsai, JH | 1 |
| Yang, P | 1 |
| Yen, JY | 1 |
| Chen, CC | 1 |
| Yang, MJ | 1 |
| Mané, A | 1 |
| Baeza, I | 1 |
| Morer, A | 1 |
| Lázaro, ML | 1 |
| Bernardo, M | 2 |
| Ziegenbein, M | 1 |
| Kropp, S | 1 |
| Hillemacher, T | 1 |
| Bleich, S | 1 |
| Fink, M | 1 |
| Taylor, MA | 1 |
| Cawrse, N | 1 |
| Wilson, S | 1 |
| Williams, M | 1 |
| Burge, T | 1 |
| Böker, H | 1 |
| Brandenberger, M | 1 |
| Schopper, C | 1 |
| Norris, B | 1 |
| Angeles, V | 1 |
| Eisenstein, R | 1 |
| Seale, JP | 1 |
| Casademont, J | 1 |
| Garrabou, G | 1 |
| Miró, O | 1 |
| López, S | 1 |
| Pons, A | 1 |
| Cardellach, F | 1 |
| Kosehasanogullari, SG | 1 |
| Akdede, B | 1 |
| Akvardar, Y | 1 |
| Akan, M | 1 |
| Tunca, Z | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Webster, P | 1 |
| Wijeratne, C | 1 |
| Raitasuo, V | 1 |
| Vataja, R | 1 |
| Elomaa, E | 1 |
| Swanson, CL | 1 |
| Price, WA | 1 |
| McEvoy, JP | 1 |
| Dave, M | 1 |
| Singer, S | 1 |
| Richards, C | 1 |
| Boland, RJ | 1 |
| Alderman, CP | 1 |
| Fraser, CD | 1 |
| Murray, S | 1 |
| Haller, E | 1 |
| Najara, JE | 1 |
| Enikeev, ID | 1 |
| Tarsy, D | 1 |
| Buckley, P | 2 |
| Levin, GM | 1 |
| Lazowick, AL | 1 |
| Powell, HS | 1 |
| Kern, JL | 1 |
| Cernek, PK | 1 |
| Bonwick, RJ | 1 |
| Hopwood, MJ | 1 |
| Morris, PL | 1 |
| Sitarz, WE | 1 |
| Meterissian, GB | 1 |
| Casey, DE | 1 |
| Simpson, GM | 1 |
| Shuster, J | 1 |
| Newman, M | 1 |
| Jampala, C | 1 |
| Bajjoka, I | 1 |
| Patel, T | 1 |
| O'Sullivan, T | 1 |
| Aguirre, C | 1 |
| García Monco, JC | 1 |
| Mendibil, B | 1 |
| Dursun, SM | 1 |
| Oluboka, OJ | 1 |
| Devarajan, S | 1 |
| Kutcher, SP | 1 |
| Hasan, S | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Koyama, T | 1 |
| Rohrbach, P | 1 |
| Collinot, JP | 1 |
| Vallet, G | 1 |
| Villanueva Lamas, J | 1 |
| García García, J | 1 |
| Alda Diez, JA | 1 |
| Tous Andreu, N | 1 |
| Lee, MS | 1 |
| Lee, HJ | 1 |
| Kim, L | 1 |
| Gram, LF | 1 |
| Masand, PS | 1 |
| Sechi, G | 1 |
| Agnetti, V | 1 |
| Masuri, R | 1 |
| Deiana, GA | 1 |
| Pugliatti, M | 1 |
| Paulus, KS | 1 |
| Rosati, G | 1 |
| Robb, AS | 1 |
| Chang, W | 1 |
| Lee, HK | 1 |
| Cook, MS | 1 |
| Reeves, RR | 2 |
| Mack, JE | 2 |
| Torres, RA | 1 |
| Rakus, A | 1 |
| Kroczak, M | 1 |
| Kontaxakis, VP | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Stamouli, SS | 1 |
| Christodoulou, GN | 1 |
| Beddingfield, JJ | 1 |
| Mann, SC | 1 |
| Campbell, EC | 1 |
| Sullivan, KA | 1 |
| Epelde Gonzalo, F | 1 |
| Bottlender, R | 1 |
| Jäger, M | 1 |
| Hofschuster, E | 1 |
| Dobmeier, P | 1 |
| Möller, HJ | 1 |
9 reviews available for risperidone and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.
Topics: Adult; Antipsychotic Agents; Catatonia; Humans; Neuroleptic Malignant Syndrome; Risperidone; Schizop | 2022 |
Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Clonazepam; Diagnosis, Differential; GABA M | 2014 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Pre | 2008 |
Risperidone-induced neuroleptic malignant syndrome: a case report and review.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examin | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Confidence Intervals; Female; | 1998 |
A case of delayed NMS induced by risperidone.
Topics: Adult; Antipsychotic Agents; Humans; Hyponatremia; Male; Neuroleptic Malignant Syndrome; Risperidone | 2000 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
1 trial available for risperidone and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Electron Transport; Electron Transp | 2007 |
88 other studies available for risperidone and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
[Neuroleptic malignant syndrome caused by olanzapine, risperidone and haloperidol].
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; | 2022 |
When the fever will not stop, stop the pills! A case report.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Quetiapine | 2023 |
Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation.
Topics: Child; Creatine Kinase; Dopamine Antagonists; Guanidinoacetate N-Methyltransferase; Humans; Language | 2020 |
Coexistence of serotonin syndrome and neuroleptic malignant syndrome: does it exist?
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone; | 2021 |
Neuroleptic Malignant Syndrome After Early Administration of Risperidone Long-Acting Injection.
Topics: Aged; Antipsychotic Agents; Humans; Injections; Male; Neuroleptic Malignant Syndrome; Risperidone | 2017 |
Pharmacist-Initiated Management of a Suspected Case of Risperidone-Induced Neuroleptic Malignant Syndrome in an Aged-Care Resident. The Role of Residential Medication Management Reviews in Medication Safety.
Topics: Aged; Antipsychotic Agents; Female; Humans; Medication Therapy Management; Neuroleptic Malignant Syn | 2020 |
Atypical neuroleptic malignant syndrome - A case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Risperidone | 2019 |
Risperidone: rhabdomyolysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Neuroleptic Malignant Sy | 2013 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Case of neuroleptic malignant syndrome with diffuse neurofibrillary tangles with calcification.
Topics: Aged; Aggression; Antipsychotic Agents; Diffuse Neurofibrillary Tangles with Calcification; Humans; | 2015 |
Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Female; Humans; Lorazepam; Neuroleptic Malignant Synd | 2014 |
A novel clinical observation in neuroleptic malignant-like syndrome: first demonstration of early progression of hydrocephalus.
Topics: Aged; Antipsychotic Agents; Depressive Disorder, Major; Disease Progression; Fatal Outcome; Female; | 2015 |
[Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
Topics: Antipsychotic Agents; Dantrolene; Female; Humans; Intellectual Disability; Middle Aged; Muscle Relax | 2016 |
Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone?
Topics: Acute Kidney Injury; Aged; Antipsychotic Agents; Clozapine; Confusion; Fever; Humans; Male; Neurolep | 2016 |
A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone.
Topics: Antipsychotic Agents; Depression; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Rispe | 2008 |
Caution is still needed when prescribing atypical antipsychotics.
Topics: Antipsychotic Agents; Catatonia; Clozapine; Humans; Neuroleptic Malignant Syndrome; Risperidone | 2008 |
Tardive seizure and antibiotics: case reports and review of the literature.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Electroconvulsive Therapy; Electroencephalography; Huma | 2008 |
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report.
Topics: Antipsychotic Agents; Catatonia; Delayed-Action Preparations; Female; Humans; Injections, Intramuscu | 2008 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, D | 2009 |
Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome.
Topics: Abnormalities, Multiple; Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Antipsychotic Agents; | 2009 |
[Peculiarities of neuroleptic syndrome in women treated with typical and atypical neuroleptics].
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2009 |
A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman.
Topics: Antipsychotic Agents; Female; Fever; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Psychotic | 2009 |
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Female; Humans; Hyperamylasemia; Injections, Intramuscular; Intubation, Gastro | 2009 |
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Resistance; | 2011 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.
Topics: Antipsychotic Agents; Catecholamines; Diagnosis, Differential; Dibenzothiazepines; Dopamine; Female; | 2011 |
Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Paliperidone | 2011 |
Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pregnancy; | 2012 |
Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Drug Interactions; Drug Therapy | 2012 |
Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Humans; Injections; Male; Middle Aged; Neuroleptic | 2013 |
Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure.
Topics: Adult; Antipsychotic Agents; Gastrointestinal Hemorrhage; Glomerulonephritis; Humans; Kidney Failure | 2002 |
A case of neuroleptic malignant syndrome with clozapine and risperidone.
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone; S | 2002 |
Neuroleptic malignant syndrome following administration of risperidone and lithium.
Topics: Adult; Humans; Lithium Chloride; Male; Neuroleptic Malignant Syndrome; Risperidone | 2003 |
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Fever; H | 2003 |
Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
Topics: Adult; Antipsychotic Agents; Creatine Kinase; Dopamine; Female; Fever; Hallucinations; Humans; Intel | 2003 |
Neuroleptic malignant syndrome and atypical antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Clozapine; Dantrolene; Dibenzothi | 2004 |
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate.
Topics: Antipsychotic Agents; Diabetic Ketoacidosis; Drug Therapy, Combination; Humans; Hyperglycemia; Lithi | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Aged; Antipsychotic Agents; Dementia; Fatal Outcome; Female; Fever; Humans; Male; Neuroleptic Malign | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Humans; Neuroleptic Malignant Synd | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Adult; Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dementia; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
Movement disorders and the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Catatonia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Lo | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Temperature; Child; Dibenz | 2005 |
Genotype A1/A2 associated with neuroleptic malignant syndrome.
Topics: Adult; Alleles; Antipsychotic Agents; Citalopram; Depressive Disorder, Major; DNA Primers; Humans; M | 2005 |
Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Blood Chemical Analysis; Catatonia; Dibenzothiepins; Disease Progression; Feve | 2005 |
Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Clozapine; Combined Modality Therapy; Electr | 2005 |
Genetic predisposition to neuroleptic malignant syndrome in siblings.
Topics: Adult; Antipsychotic Agents; Citalopram; Female; Humans; Male; Neuroleptic Malignant Syndrome; Polym | 2006 |
Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia.
Topics: Adult; Antipsychotic Agents; Catatonia; Electroshock; Female; Humans; Neuroleptic Malignant Syndrome | 2006 |
Neuroleptic malignant syndrome in the burns patient?
Topics: Antipsychotic Agents; Burns; Depressive Disorder; Fatal Outcome; Female; Fever; Humans; Middle Aged; | 2006 |
[Neurotoxicity related to lithium-risperidon combination treatment in a patient with schizoaffective disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Cognition Disorders; Drug Interactions; Drug Therapy, Combin | 2007 |
Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration.
Topics: Female; Fever; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Risperidone; Time Factors | 2006 |
Neuroleptic malignant syndrome caused by combination of risperidone and lithium in a patient with multiple medical comorbidities.
Topics: Anemia, Hypochromic; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; beta-Thalassemia; | 2007 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Risperidone-induced neuroleptic malignant syndrome.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Neuroleptic Maligna | 1994 |
Risperidone-induced neuroleptic malignant syndrome in young patient.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; | 1994 |
Effects of concomitant risperidone and lithium treatment.
Topics: Antipsychotic Agents; Confusion; Creatine Kinase; Drug Therapy, Combination; Fever; Humans; Isoxazol | 1995 |
Two cases of risperidone-induced neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Piperidines | 1995 |
Two cases of risperidone-induced neuroleptic malignant syndrome.
Topics: Aged; Antipsychotic Agents; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Piperidines; R | 1995 |
Use of risperidone with a patient sensitive to conventional neuroleptic drugs.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Isoxazoles; Male; Middle Aged; Neuroleptic Malignant | 1995 |
Risperidone and NMS?
Topics: Adult; Antipsychotic Agents; Female; Humans; Neuroleptic Malignant Syndrome; Psychotic Disorders; Ri | 1995 |
Risperidone and neuroleptic malignant syndrome: a case report.
Topics: Adult; Female; Humans; Neuroleptic Malignant Syndrome; Psychotic Disorders; Risperidone | 1995 |
Risperidone and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Female; Humans; Neuroleptic Malignant Syndrome; R | 1996 |
Novel antipsychotics and neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Diagnosis, Differential; Humans; Neuroleptic Malignant Syndrome; Risk Factors; | 1996 |
Neuroleptic malignant syndrome with risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Intellectual Disability; Male | 1996 |
Delayed risperidone-induced neuroleptic malignant syndrome.
Topics: Aged; Antipsychotic Agents; Fatal Outcome; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone | 1996 |
Neuroleptic malignant syndrome and risperidone: a case report.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Male; Neuroleptic M | 1996 |
Comment: delayed risperidone-induced neuroleptic malignant syndrome.
Topics: Antimanic Agents; Drug Interactions; Humans; Lithium Chloride; Neuroleptic Malignant Syndrome; Parox | 1996 |
EPS with fever versus NMS.
Topics: Basal Ganglia Diseases; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Female; | 1996 |
Risperidone and neuroleptic malignant syndrome. Recognizing a potentially fatal condition.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Patient Education | 1997 |
Atypical neuroleptic malignant syndrome associated with risperidone treatment.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Middle Aged; Muscle Rigidity; Neuroleptic Ma | 1997 |
Risperidone-induced neuroleptic malignant syndrome.
Topics: Aged; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone | 1997 |
[Malignant neuroleptic syndrome associated to risperidone].
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Humans; Male; Neuroleptic Malignant Syndrome; Ris | 1998 |
High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome.
Topics: Aged; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Neuroleptic Malignant Syndrom | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
[Neuroleptic malignant syndrome induced by risperidone].
Topics: Antipsychotic Agents; Female; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Risperidone | 1998 |
[The risperidone-associated neuroleptic malignant syndrome in a pediatric patient].
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Neuroleptic Malignant Syndrome; Risperidone; Schiz | 1998 |
[Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Neuroleptic Mal | 2000 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies.
Topics: Antipsychotic Agents; Female; Humans; Lewy Body Disease; Middle Aged; Neuroleptic Malignant Syndrome | 2000 |
Case study. Risperidone-Induced neuroleptic malignant syndrome in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Neuroleptic Malignant Syndrome; | 2000 |
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Risper | 2001 |
[Neuroleptic malignant syndrome--case report].
Topics: Aged; Antipsychotic Agents; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Neuroleptic Ma | 2001 |
Toxic interaction between risperidone and clozapine: a case report.
Topics: Adult; Antipsychotic Agents; Clozapine; Diagnosis, Differential; Drug Interactions; Humans; Male; Ne | 2002 |
Neurotoxic syndrome associated with risperidone and fluvoxamine.
Topics: Adult; Antipsychotic Agents; Drug Interactions; Female; Fluvoxamine; Humans; Neuroleptic Malignant S | 2002 |
[Malignant neuroleptic syndrome and hyponatremia associated with risperidone poisoning].
Topics: Adult; Antipsychotic Agents; Humans; Hyponatremia; Male; Neuroleptic Malignant Syndrome; Risperidone | 2002 |
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Female; Humans; Middle Aged; Neuroleptic Malignant Syn | 2002 |